These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32251732)

  • 1. Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage.
    Olsen M; Cook SE; Huang V; Pedersen N; Murphy BG
    Int J Antimicrob Agents; 2020 Jun; 55(6):105964. PubMed ID: 32251732
    [No Abstract]   [Full Text] [Related]  

  • 2. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
    Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
    Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status on treatment options for feline infectious peritonitis and SARS-CoV-2 positive cats.
    Izes AM; Yu J; Norris JM; Govendir M
    Vet Q; 2020 Dec; 40(1):322-330. PubMed ID: 33138721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
    Fu L; Ye F; Feng Y; Yu F; Wang Q; Wu Y; Zhao C; Sun H; Huang B; Niu P; Song H; Shi Y; Li X; Tan W; Qi J; Gao GF
    Nat Commun; 2020 Sep; 11(1):4417. PubMed ID: 32887884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purposing Saikosaponins for the treatment of COVID-19.
    Bahbah EI; Negida A; Nabet MS
    Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
    [No Abstract]   [Full Text] [Related]  

  • 6. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.
    Vuong W; Khan MB; Fischer C; Arutyunova E; Lamer T; Shields J; Saffran HA; McKay RT; van Belkum MJ; Joyce MA; Young HS; Tyrrell DL; Vederas JC; Lemieux MJ
    Nat Commun; 2020 Aug; 11(1):4282. PubMed ID: 32855413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs and the renin-angiotensin system in covid-19.
    Aronson JK; Ferner RE
    BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
    [No Abstract]   [Full Text] [Related]  

  • 8. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.
    South AM; Tomlinson L; Edmonston D; Hiremath S; Sparks MA
    Nat Rev Nephrol; 2020 Jun; 16(6):305-307. PubMed ID: 32246101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Antiviral Options against SARS-CoV-2 Infection.
    Ianevski A; Yao R; Fenstad MH; Biza S; Zusinaite E; Reisberg T; Lysvand H; Løseth K; Landsem VM; Malmring JF; Oksenych V; Erlandsen SE; Aas PA; Hagen L; Pettersen CH; Tenson T; Afset JE; Nordbø SA; Bjørås M; Kainov DE
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32545799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
    Vardhan S; Sahoo SK
    Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?
    Somanath PR
    Am J Physiol Lung Cell Mol Physiol; 2020 Jul; 319(1):L45-L47. PubMed ID: 32519895
    [No Abstract]   [Full Text] [Related]  

  • 12. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.
    Dabaghian F; Khanavi M; Zarshenas MM
    Med Hypotheses; 2020 Oct; 143():109841. PubMed ID: 32425303
    [No Abstract]   [Full Text] [Related]  

  • 13. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
    Carradori S
    Antiinflamm Antiallergy Agents Med Chem; 2020; 19(2):85-87. PubMed ID: 32213152
    [No Abstract]   [Full Text] [Related]  

  • 14. Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication.
    Pang X; Cui Y; Zhu Y
    Acta Pharmacol Sin; 2020 Sep; 41(9):1255-1257. PubMed ID: 32581256
    [No Abstract]   [Full Text] [Related]  

  • 15. Can beta-adrenergic blockers be used in the treatment of COVID-19?
    Vasanthakumar N
    Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
    [No Abstract]   [Full Text] [Related]  

  • 16. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2.
    Han Y; Král P
    ACS Nano; 2020 Apr; 14(4):5143-5147. PubMed ID: 32286790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Proteases for Treating COVID-19.
    Luan B; Huynh T; Cheng X; Lan G; Wang HR
    J Proteome Res; 2020 Nov; 19(11):4316-4326. PubMed ID: 33090793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is SARS-CoV-2 associated with liver dysfunction in COVID-19 patients?
    Ali N
    Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):e84-e86. PubMed ID: 32471656
    [No Abstract]   [Full Text] [Related]  

  • 19. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.
    Dastan F; Abedini A; Shahabi S; Kiani A; Saffaei A; Zare A
    Iran J Allergy Asthma Immunol; 2020 May; 19(S1):10-12. PubMed ID: 32534505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response.
    Ryan PM; Caplice N
    Open Heart; 2020 Jun; 7(1):. PubMed ID: 32532804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.